Dalfampridine: A brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis

Current Medical Research and Opinion

Volumn 27, Issue 7, 2011, Pages 1415-1423

  Dunn, Jeffrey ^a   Blight, Andrew ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b ACORDA THERAPEUTICS INC   (United States)

Author keywords

4 Aminopyridine; Ambulation; Dalfampridine; Fampridine; Multiple sclerosis; Potassium channels

Indexed keywords

4 AMINOPYRIDINE; AMPYRA; DALFAMPRIDINE; IMMUNOMODULATING AGENT; NATALIZUMAB; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ACTION POTENTIAL; AREA UNDER THE CURVE; ASTHENIA; CLINICAL TRIAL (TOPIC); CONCENTRATION RESPONSE; CONVULSION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG TOXICITY; FOCAL EPILEPSY; HEADACHE; HUMAN; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MEMBRANE POTENTIAL; MULTIPLE SCLEROSIS; NAUSEA; NERVE CONDUCTION; NERVE FIBER MEMBRANE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; TREATMENT OUTCOME; URINARY TRACT INFECTION; WALKING SPEED;

4-AMINOPYRIDINE; ANIMALS; AXONS; HUMANS; MULTIPLE SCLEROSIS; NERVE FIBERS, MYELINATED; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; TREATMENT OUTCOME; WALKING;

EID: 79958863778     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.583229     Document Type: Review

References (82)

1. About MS. Available at: http://www.nationalmssociety.org/about- multiplesclerosis/index.aspx [Last accessed 6 September 2010].
2. Waxman SG. Conduction in myelinated, unmyelinated, and demyelinated fibers. Arch Neurol 1977;34:585-9. (Pubitemid 8199510)
3. Smith KJ, McDonald WI. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 1999;354:1649-73. (Pubitemid 29534432)
4. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65-70. (Pubitemid 32053209)
5. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999;12:295-302. (Pubitemid 29378163)
6. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003;206:165-71. (Pubitemid 36143722)
7. Goodin DS, Frohman EM, Garmany Jr GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-78. Erratum in: Neurology 2002;59:480. (Pubitemid 34086933)
8. Crayton HJ, Rossman HS. Managing the symptoms of multiple sclerosis: a multimodal approach. Clin Ther 2006;28:445-60. (Pubitemid 43796316)
9. Henze T. What is new in symptom management? Int Mult Scler J 2007;14:22-7. (Pubitemid 46917296)
10. Boissy AR, Cohen JA. Multiple sclerosis symptom management. Expert Rev Neurother 2007;7:1213-22. (Pubitemid 47451027)
11. Swingler RJ, Compston DA. The morbidity of multiple sclerosis. Q J Med 1992;83:325-37.
12. Wu N, Minden SL, Hoaglin DC, et al. Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. J Health Hum Serv Adm 2007;30:233-67.
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52. (Pubitemid 14237132)
14. Fischer JS, Rudick RA, Cutter GR, et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5:244-50. (Pubitemid 29405620)
15. Barnes D, Hughes RA, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997;349:902-6. (Pubitemid 27139818)
16. Milligan N, Newcombe R, Compston D. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-6. (Pubitemid 17067536)
17. Patzold T, Schwengelbeck M, Ossege LM, et al. Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis. Acta Neurol Scand 2002; 105:164-8. (Pubitemid 34258956)
18. Humm AM, Z'Graggen WJ, Bü hler R, et al. Quantification of central motor conduction deficits in multiple sclerosis patients before and after treatment of acute exacerbation by methylprednisolone. J Neurol Neurosurg Psychiatry 2006;77:345-50.
19. Brown TR, Kraft GH. Exercise and rehabilitation for individuals with multiple sclerosis. Phys Med Rehabil Clin N Am 2005;16:513-55. (Pubitemid 40704682)
20. Khan F, Turner-Stokes L, Ng L, et al. Multidisciplinary rehabilitation for adults with multiple sclerosis. Cochrane Database Syst Rev 2007;2:CD006036.
21. Goodman AD, Brown TR, Cohen JA, et al. Dose-comparison trial of sustainedrelease fampridine in multiple sclerosis. Neurology 2008;71:1134-41.
22. Goodman AD, Brown TR, Krupp L, et al. Sustained release of oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373:732-8.
23. Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010; 68:494-502.
24. Ampyra (dalfampridine) extended release tablets [prescribing information]. Hawthorne, NY, USA: Acorda Therapeutics, Inc., January 2010.
25. Blight AR. Computer simulation of action potentials and afterpotentials in mammalian myelinated axons: the case for a lower resistance myelin sheath. Neuroscience 1985;15:13-31. (Pubitemid 15008572)
26. Waxman SG. Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med 1982;306:1529-33. (Pubitemid 12123934)
27. Waxman SG. Ion channels and neuronal dysfunction in multiple sclerosis. Arch Neurol 2002;59:1377-80. (Pubitemid 35014801)
28. Chiu SY. The roles of potassium and calcium channels in physiology and pathophysiology of axons. In: Waxman SG (ed.) Multiple Sclerosis as a Neuronal Disease. Amsterdam: Elsevier Academic Press, 2005.
29. Coetzee WA, Amarillo Y, Chiu J, et al. Molecular diversity of K\+channels. Ann N Y Acad Sci 1999;868:233-85.
30. Rudy B. Voltage-gated K\+channels. In: Kew J, Davies C (eds) Ion Channels, From Structure to Function. Oxford: Oxford University Press, 2010:21-57.
31. Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007;13:357-68. (Pubitemid 46705997)
32. Judge SI, Bever Jr CT. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 2006;111:224-59. (Pubitemid 43765538)
33. Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980;283:570-2. (Pubitemid 10136031)
34. Targ EF, Kocsis JD. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985;328:358-61. (Pubitemid 15135163)
35. Shi R, Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997;77:553-62. (Pubitemid 27079623)
36. Shi R, Kelly TM, Blight AR. Conduction block in acute and chronic spinal cord injury: different dose-response characteristics for reversal by 4-aminopyridine. Exp Neurol 1997;148:495-501. (Pubitemid 28068844)
37. Karimi-Abdolrezaee S, Eftekharpour E, Fehlings MG. Temporal and spatial patterns of Kv1.1 and Kv1.2 protein and gene expression in spinal cord white matter after acute and chronic spinal cord injury in rats: implications for axonal pathophysiology after neurotrauma. Eur J Neurosci 2004;19:577-89. (Pubitemid 38241297)
38. Fehlings MG, Nashmi R. Changes in pharmacological sensitivity of the spinal cord to potassium channel blockers following acute spinal cord injury. Brain Res 1996;736:135-45. (Pubitemid 26356470)
39. Lundh H. Effects of 4-aminopyridine on neuromuscular transmission. Brain Res 1978;153:307-18. (Pubitemid 8387960)
40. Kim YI, Goldner MM, Sanders DB. Facilitatory effects of 4-aminopyridine on neuromuscular transmission in disease states. Muscle Nerve 1980;3:112-9. (Pubitemid 10134617)
41. Smith KJ, Felts PA, John GR. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain 2000;123:171-84. (Pubitemid 30037979)
42. Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990;27:186-92. (Pubitemid 20086640)
43. Jones RE, Heron JR, Foster DH, et al. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 1983;60:353-62. (Pubitemid 13051185)
44. Stefoski D, Davis FA, Faut M, et al. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987;21:71-7. (Pubitemid 17004147)
45. Stefoski D, Davis FA, Fitzsimmons WE, et al. 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology 1991;41:1344-8.
46. Bever Jr CT, Young D, Anderson PA, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994; 44:1054-9. (Pubitemid 24188176)
47. Schwid SR, Petrie MD, McDermott MP, et al. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997;48:817-21.
48. Van Diemen HA, Polman CH, van Dongen TM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992;32:123-30.
49. Sharrack B, Hughes RA. Clinical scales for multiple sclerosis. J Neurol Sci 1996;135:1-9. (Pubitemid 26019015)
50. Hobart JC, Freeman J, Thompson A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain 2000;23:1027-40. (Pubitemid 30224198)
51. Albrecht H, Wotzel C, Erasmus LP, et al. Day-to-day variability of maximum walking distance in MS patients can mislead to relevant changes in the Expanded Disability Status Scale (EDSS): average walking speed is a more constant parameter. Mult Scler 2001;7:105-9. (Pubitemid 32514525)
52. Report: 2006 Limited FDA Survey of Compounded Drug Products. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ PharmacyCompounding/ucm204237.htm [Last accessed 6 September 2010].
53. Johnson NC, Morgan MW. An unusual case of 4-aminopyridine toxicity. J Emerg Med 2006;30:175-7.
54. Pickett TA, Enns R. Atypical presentation of 4-aminopyridine overdose. Ann Emerg Med 1996;3:382-5. (Pubitemid 26085022)
55. Smeets JW, Kunst MW. Severe poisoning by 4-aminopyridine in a body builder. Ned Tijdschr Geneeskd 1995;139:2667-9. (Pubitemid 26021056)
56. Spyker DA, Lynch C, Shabanowitz J, et al. Poisoning with 4-aminopyridine: report of three cases. Clin Toxicol 1980;16:487-97. (Pubitemid 10048631)
57. Stork CM, Hoffman RS. Characterization of 4-aminopyridine in overdose. J Toxicol Clin Toxicol 1994;32:583-7. (Pubitemid 24332007)
58. Burton JM, Bell CM, Walker SE, et al. 4-Aminopyridine toxicity with unintentional overdosage in four patients with multiple sclerosis. Neurology 2008; 71:1833-4.
59. Schwam E. Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error. J Emerg Med 2009;May 12 [Epub ahead of print].
60. De Cauwer H, De Wolf P, Couvreur F, et al. An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy? Acta Neurol Belg 2009;109:40-1.
61. Uges DR, Sohn YJ, Greijdanus B, et al. 4-aminopyridine kinetics. Clin Pharmacol Ther 1982;31:587-93. (Pubitemid 13105517)
62. Hayes KC, Katz MA, Devane JG, et al. Pharmacokinetics of an immediaterelease oral formulation of fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol 2003;43:379-85. (Pubitemid 36368779)
63. Vollmer T, Henney 3rd HR. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a phase I-II, open-label trial. Clin Ther 2009;31:2206-14.
64. Vollmer T, Blight AR, Henney 3rd HR. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Clin Ther 2009;31:2215-23.
65. Smith W, Swan S, Marbury T, et al. Single-dose pharmacokinetics of sustained- release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment. J Clin Pharmacol 2010;50:151-9.
66. Nilsagard Y, Lundholm C, Gunnarsson L-G, et al. Clinical relevance using timed walk tests and 'timed up and go' testing in persons with multiple sclerosis. Physiother Res Int 2007;12:105-14.
67. Hoogervorst EL, Kalkers NF, Cutter GR, et al. The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite. Mult Scler 2004;10:55-60. (Pubitemid 38100527)
68. Kaufman M, Moyer D, Norton J. The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite. Mult Scler 2000;6:286-90.
69. Kragt JJ, van der Linden FA, Nielsen JM, et al. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler 2006;12:594-8. (Pubitemid 46940633)
70. Schwid SR, Goodman AD, McDermott MP, et al. Quantitative functional measures in MS: what is a reliable change? Neurology 2002;58:1294-6. (Pubitemid 34411881)
71. Hobart JC, Riazi A, Lamping DL, et al. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 2003;60:31-6. (Pubitemid 36070640)
72. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-87.
73. Leary SM, Thompson AJ. Interferon beta-1a in primary progressive multiple sclerosis. J Neurol Sci 2003;206:215-16. (Pubitemid 36143731)
74. Belachew S, Phan-Ba R, Bartholome E, et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2011; 18:240-5.
75. Acorda Therapeutics: Data on File. Integrated Summary of Safety. Fampridine-SR in Patients With Multiple Sclerosis. NDA 22-250, 2009.
76. Eriksson M, Ben-Menachem E, Andersen O. Epileptic seizures, cranial neuralgias and paroxysmal symptoms in remitting and progressive multiple sclerosis. Mult Scler 2002;8:495-9. (Pubitemid 35396399)
77. Koch M, Uyttenboogaart M, Polman S, et al. Seizures in multiple sclerosis. Epilepsia 2008;49:948-53. (Pubitemid 351794011)
78. Kelley BJ, Rodriguez M. Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management. CNS Drugs 2009;23:805-15.
79. Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004; 15:475-95. (Pubitemid 38510109)
80. March B, Cardi T. Assessment of the cardiac safety of fampridine-SR sustained- release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals. Expert Opin Investig Drugs 2009;18:1807-15.
81. Renganathan M, Sidach S, Blight AR. Effects of 4-aminopyridine on cloned hERG channels expressed in mammalian cells. Arch Drug Info 2009;2:51-7.
82. Thomas G, Klatt B, Blight A. Effect of 4-aminopyridine on action potential parameters in isolated dog Purkinje fibers. Arch Drug Info 2010;3:19-25